Decitabine

Injection

To Be Discontinued Active (discontinuing) — Day 83 FDA record updated 02/20/2026

High impact — Sole-source drug with no supply currently available from this manufacturer.

Editor of record: Branmoor Editorial · [email protected]

FDA shortage record

Substance

Decitabine

Manufacturers / suppliers

BluePoint Laboratories
Ingenus Pharmaceuticals LLC

2 known suppliers in current FDA data

Dosage form

Injection

Presentation

Decitabine, Injection, 50 mg (NDC 68001-573-41)

Route(s)

INTRAVENOUS

Therapeutic category

Oncology

Package NDC

68001-573-41

Initially posted

02/20/2026

Days on shortage list

Discontinued

02/20/2026

Current FDA status

To Be Discontinued

Shortage entries (current dataset)

1 record for Decitabine

Why this shortage matters

Oncology drugs treat cancers including solid tumors, leukemia, and lymphoma. Shortages of chemotherapy agents can delay or interrupt regimens where dose timing and intensity directly affect treatment outcomes.

FDA therapeutic class: Oncology

Reason and context

Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug

Manufacturer contact

Per the FDA record, the manufacturer's contact for supply inquiries is 866-321-5031.

If you're affected by this shortage

Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
Ask your pharmacy to check supply across multiple wholesalers and other branches.
Check current pharmacy pricing and availability via GoodRx (affiliate link).
Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.

Sources

FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
FDA Structured Product Label (SPL set ID 6c6ab831-6234-4803-8a01-5c51ec3b0716).
FDA UNII identifier: 776B62CQ27.
See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.

Important

This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.